<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1988">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04387292</url>
  </required_header>
  <id_info>
    <org_study_id>MMT_2020_12</org_study_id>
    <nct_id>NCT04387292</nct_id>
  </id_info>
  <brief_title>Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic</brief_title>
  <acronym>SOCOVID</acronym>
  <official_title>Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ophthalmologic damages secondary to COVID-19 coronavirus infection are little described. The&#xD;
      ocular involvement is probably multiple, ranging from pathologies of the anterior segment&#xD;
      such as conjunctivitis and anterior uveitis to disorders that threaten vision such as&#xD;
      retinitis or optic neuropathy. On the other hand, in addition to this impairment, when&#xD;
      patients are hospitalized for acute respiratory failure, complications related to possible&#xD;
      resuscitation, medication prescriptions, positioning and oxygenation.&#xD;
&#xD;
      COVID-19 itself, has several components:&#xD;
&#xD;
        -  An apoptotic action of the viral attack which will generate cellular destruction,&#xD;
           whether pulmonary, cardiac or renal or maybe ocular&#xD;
&#xD;
        -  A secondary autoimmune action with the development of major vascular inflammation,&#xD;
           possibly reaching the retinal, choroidal, and optic nerve vessels. A secondary &quot;hyper&quot;&#xD;
           inflammatory syndrome with flashing hypercytokinemia and multi-organ decompensation is&#xD;
           described in 3,7% to 4 ,3% of severe cases.&#xD;
&#xD;
        -  A thromboembolic action&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Upon discharge from hospital for COVID-19 infection (or during a telephone call for patients&#xD;
      already discharged at the start of the study), patients will be informed of the study. An&#xD;
      ophthalmology appointment will be given to them between 4 and 6 months after their discharge.&#xD;
&#xD;
      During the ophthalmology appointment, the patient's clinical data will be collected during an&#xD;
      interview (medical and treatment history, blood group). The patient will benefit from a full&#xD;
      ophthalmological examination.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 7, 2020</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Description of the ophthalmological problems observed</measure>
    <time_frame>6 months after discharge of hospitalization</time_frame>
    <description>Multimodal ophthalmologic imaging</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>COVID19</condition>
  <condition>Ophthalmopathy</condition>
  <arm_group>
    <arm_group_label>Ophthalmologic exam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ophthalmologic exam</intervention_name>
    <description>Visual acuity (ETDRS exam)&#xD;
Slit lamp examination : fluorescein test, Oxford score, break up time, Schirmer II test&#xD;
Lipiview&#xD;
Eye pressure measurement (air tonometer)&#xD;
Wide field retinophotography&#xD;
Multicolor and auto-fluorescence retinophotography&#xD;
Indocyanine green retinal angiography&#xD;
Optical coherence tomography (OCT) B posterior pole scan&#xD;
OCT Angiography (OCT-A) of the optic nerve and posterior pole&#xD;
Adaptive optics&#xD;
Visual field (Humphrey)</description>
    <arm_group_label>Ophthalmologic exam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients having been hospitalized for a confirmed COVID-19 infection (CT-scanner or&#xD;
             PCR- Polymerase chain reaction)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martine MAUGET FAYSSE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondation A. de Rothschild</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Am√©lie YACHITZ, MD</last_name>
    <phone>(0)148036454</phone>
    <phone_ext>+33</phone_ext>
    <email>ayavchitz@for.paris</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vivien VASSEUR</last_name>
    <phone>(0)148036440</phone>
    <phone_ext>+33</phone_ext>
    <email>vvasseur@for.paris</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fondation A de Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martine MAUGET FAYSSE, MD</last_name>
      <phone>(0)148036437</phone>
      <phone_ext>+33</phone_ext>
      <email>mmfaysse@for.paris</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 12, 2020</study_first_submitted>
  <study_first_submitted_qc>May 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2020</study_first_posted>
  <last_update_submitted>September 11, 2020</last_update_submitted>
  <last_update_submitted_qc>September 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

